Rhumbline Advisers An2 Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023
SELL
$7.58 - $16.08 $10,816 - $22,946
-1,427 Reduced 85.09%
250 $4,000
Q2 2023

Aug 08, 2023
SELL
$5.06 - $9.91 $50,766 - $99,427
-10,033 Reduced 85.68%
1,677 $14,000
Q1 2023

May 11, 2023
BUY
$7.94 - $15.6 $12,926 - $25,396
1,628 Added 16.15%
11,710 $116,000
Q4 2022

Feb 14, 2023
BUY
$8.51 - $19.69 $85,797 - $198,514
10,082 New
10,082 $96,000

Others Institutions Holding ANTX

# of Institutions
33
Shares Held
13.5M
Call Options Held
0
Put Options Held
0
View Full List

About AN2 Therapeutics, Inc.

ANTX Quotes by TradingView
  • Ticker ANTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,402,700
  • Market Cap $32.4M
  • Description
  • AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...
More about ANTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email